Biological Lattice Industries Corp.

Biological Lattice Industries Corp. (BLI) is a deep-tech startup that specializes in biofabrication and life sciences research and development. The company has developed an integrated, end-to-end platform that combines hardware and software to automate and streamline laboratory workflows. Its flagship offering includes Loominus Studio, a no-code, unified software platform that enables researchers to design, manage, and automate complex biofabrication workflows. This is complemented by the BioLoom, a multi-tool, extrusion-based 3D bioprinter that features active environmental control to ensure high-resolution, reproducible printing of biomaterials and devices. By unifying these tools, BLI aims to replace fragmented manual processes with an intelligent, automated system that bridges the gap between digital design and physical fabrication.

This technology is designed to assist life sciences researchers in accelerating the development of advanced medical and biological applications, such as 3D cell culture systems for human biology emulation, drug delivery platforms, and resorbable medical devices. By providing a scalable, GMP-compliant solution that emphasizes reproducibility and precision, BLI enables laboratories to improve operational efficiency and fast-track the commercialization of their research. The company, founded in 2021 with roots at MIT, operates with a global presence, maintaining its headquarters in Boston and research operations at the Lefkippos Technological Park in Greece. Supported by venture capital, the company aims to establish its platform as an industry standard for biofabrication labs worldwide.